NEWS: GlycoBac develops Sf-RVN, a new Sf-rhabdovirus-free S. frugiperda cell line for recombinant protein production
GlycoBac is currently providing Sf-RVN cells to interested parties under commercial Materials Transfer Agreements (for evaluation) and/or licensing agreements (for application) in various fields of use.
Please contact Dr. Jarvis directly for additional information.
Read another peer-reviewed paper published in the Elsevier journal 'Biologicals' about endogenous viral elements discovered by GlycoBac in Sf-RVN and other cell lines
Sf-RVN cells are a safer alternative to commonly used
S. frugiperda cell lines. Listen to Prof. Dr. Jarvis talk about
Sf-RVN cells and how they compare to Sf9 cells: